Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors. (October 2020) - Papadopoulos, K.; Sharma, M.; Hamilton, E.; Richardson, D.; Bashir, B.; Hodgson, G.; Ke, N.; Kang-Fortner, Q.; Zhou, L.; Zamboni, W.; Jolin, H.; Madigan, C.; et al.